Recent MRK News
- KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial • Business Wire • 11/12/2024 11:45:00 AM
- Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024 • Business Wire • 11/12/2024 08:00:00 AM
- L'Agence canadienne des médicaments recommande le remboursement de WINREVAIR® (sotatercept) • PR Newswire (Canada) • 11/08/2024 08:04:00 PM
- Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement • PR Newswire (Canada) • 11/08/2024 07:47:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/06/2024 09:09:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 09:05:36 PM
- Merck to Participate in the UBS Global Healthcare Conference • Business Wire • 11/06/2024 11:45:00 AM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 11/04/2024 03:05:27 PM
- U.S. Index Futures Decline; Oil Prices Rise on Strong Demand and OPEC+ Production Outlook • IH Market News • 10/31/2024 11:15:53 AM
- Microsoft and Meta Decline Up to 4%; Roku Falls 14% Amid Lower Estimates; Booking Surges 6%; Carvana Soars 20% • IH Market News • 10/31/2024 11:13:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2024 10:44:02 AM
- Merck Announces Third-Quarter 2024 Financial Results • Business Wire • 10/31/2024 10:30:00 AM
- Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 10/28/2024 10:45:00 AM
- Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers • Business Wire • 10/24/2024 10:45:00 AM
- CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older • Business Wire • 10/23/2024 11:58:00 PM
- Higher Treasury Yields May Lead To Extended Pullback On Wall Street • IH Market News • 10/22/2024 01:08:50 PM
- US Futures Slip as Investors Eye Q3 Earnings; Oil Prices Drop • IH Market News • 10/22/2024 10:08:22 AM
- Dow Gives Back Ground But Nasdaq Closes In Positive Territory • IH Market News • 10/21/2024 08:44:00 PM
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 • Business Wire • 10/19/2024 09:09:00 PM
- Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants • Business Wire • 10/17/2024 10:00:00 PM
- Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease • Business Wire • 10/16/2024 10:45:00 AM
- Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma • Business Wire • 10/14/2024 12:00:00 PM
- New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio • Business Wire • 10/09/2024 10:45:00 AM
- Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma • Business Wire • 10/08/2024 10:45:00 AM
- Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • InvestorsHub NewsWire • 10/03/2024 12:45:00 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM